Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35244
- GSK Investigational Site
-
Birmingham、Alabama、アメリカ、35205
- GSK Investigational Site
-
Dothan、Alabama、アメリカ、36305
- GSK Investigational Site
-
-
Arkansas
-
Benton、Arkansas、アメリカ、72019
- GSK Investigational Site
-
Conway、Arkansas、アメリカ、72034
- GSK Investigational Site
-
Fayetteville、Arkansas、アメリカ、72703
- GSK Investigational Site
-
Jonesboro、Arkansas、アメリカ、72401
- GSK Investigational Site
-
Little Rock、Arkansas、アメリカ、72205
- GSK Investigational Site
-
-
California
-
Huntington Beach、California、アメリカ、92647
- GSK Investigational Site
-
Long Beach、California、アメリカ、90806
- GSK Investigational Site
-
Paramount、California、アメリカ、90723
- GSK Investigational Site
-
Sacramento、California、アメリカ、95816
- GSK Investigational Site
-
San Francisco、California、アメリカ、94102
- GSK Investigational Site
-
West Covina、California、アメリカ、91790
- GSK Investigational Site
-
-
Colorado
-
Longmont、Colorado、アメリカ、80501
- GSK Investigational Site
-
-
Connecticut
-
Norwich、Connecticut、アメリカ、06360
- GSK Investigational Site
-
-
Idaho
-
Nampa、Idaho、アメリカ、83686
- GSK Investigational Site
-
-
Illinois
-
DeKalb、Illinois、アメリカ、60115
- GSK Investigational Site
-
-
Indiana
-
New Albany、Indiana、アメリカ、47150
- GSK Investigational Site
-
-
Kansas
-
Arkansas City、Kansas、アメリカ、67005
- GSK Investigational Site
-
Newton、Kansas、アメリカ、67114
- GSK Investigational Site
-
Wichita、Kansas、アメリカ、67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown、Kentucky、アメリカ、40004
- GSK Investigational Site
-
Louisville、Kentucky、アメリカ、40207
- GSK Investigational Site
-
-
Louisiana
-
Bossier City、Louisiana、アメリカ、71111
- GSK Investigational Site
-
Metairie、Louisiana、アメリカ、70006
- GSK Investigational Site
-
-
Michigan
-
Stevensville、Michigan、アメリカ、49127
- GSK Investigational Site
-
-
Minnesota
-
Saint Paul、Minnesota、アメリカ、55108
- GSK Investigational Site
-
-
Missouri
-
Saint Louis、Missouri、アメリカ、63141
- GSK Investigational Site
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68134
- GSK Investigational Site
-
-
Nevada
-
Henderson、Nevada、アメリカ、89015
- GSK Investigational Site
-
-
New York
-
Cortland、New York、アメリカ、13045
- GSK Investigational Site
-
-
North Carolina
-
Boone、North Carolina、アメリカ、28607
- GSK Investigational Site
-
Cary、North Carolina、アメリカ、27518
- GSK Investigational Site
-
Raleigh、North Carolina、アメリカ、27609
- GSK Investigational Site
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58103
- GSK Investigational Site
-
-
Ohio
-
Austintown、Ohio、アメリカ、44515
- GSK Investigational Site
-
Cincinnati、Ohio、アメリカ、45245
- GSK Investigational Site
-
Cleveland、Ohio、アメリカ、44121
- GSK Investigational Site
-
Dayton、Ohio、アメリカ、45406
- GSK Investigational Site
-
-
Oregon
-
Gresham、Oregon、アメリカ、97030
- GSK Investigational Site
-
-
Pennsylvania
-
Erie、Pennsylvania、アメリカ、16505
- GSK Investigational Site
-
Greenville、Pennsylvania、アメリカ、16125
- GSK Investigational Site
-
Latrobe、Pennsylvania、アメリカ、15650
- GSK Investigational Site
-
Pittsburgh、Pennsylvania、アメリカ、15236
- GSK Investigational Site
-
Uniontown、Pennsylvania、アメリカ、15401
- GSK Investigational Site
-
Wexford、Pennsylvania、アメリカ、15090
- GSK Investigational Site
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29406
- GSK Investigational Site
-
-
Tennessee
-
Clarksville、Tennessee、アメリカ、37043
- GSK Investigational Site
-
Jackson、Tennessee、アメリカ、38305
- GSK Investigational Site
-
Kingsport、Tennessee、アメリカ、37660
- GSK Investigational Site
-
-
Texas
-
Austin、Texas、アメリカ、78705
- GSK Investigational Site
-
Fort Worth、Texas、アメリカ、76135
- GSK Investigational Site
-
Houston、Texas、アメリカ、77055
- GSK Investigational Site
-
San Angelo、Texas、アメリカ、76904
- GSK Investigational Site
-
-
Utah
-
Bountiful、Utah、アメリカ、84010
- GSK Investigational Site
-
Layton、Utah、アメリカ、84041
- GSK Investigational Site
-
Murray、Utah、アメリカ、84107
- GSK Investigational Site
-
Provo、Utah、アメリカ、84604
- GSK Investigational Site
-
Roy、Utah、アメリカ、84067
- GSK Investigational Site
-
South Jordan、Utah、アメリカ、84095
- GSK Investigational Site
-
-
Virginia
-
Burke、Virginia、アメリカ、22015
- GSK Investigational Site
-
-
-
-
-
Bangkok、タイ、10400
- GSK Investigational Site
-
-
-
-
-
Mexico、メキシコ、6720
- GSK Investigational Site
-
Mexico city、メキシコ、04530
- GSK Investigational Site
-
-
-
-
-
Taipei、台湾、104
- GSK Investigational Site
-
Taipei、台湾
- GSK Investigational Site
-
-
-
-
-
Pokfulam、香港
- GSK Investigational Site
-
Shatin、香港
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
- Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject's parent/guardian.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
- History of hypersensitivity to any vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- Acute disease at the time of enrolment.
- History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
- Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Fluarix Dose A Group
Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
実験的:Fluarix Dose B Group
Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
アクティブコンパレータ:Fluzone Group
Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
時間枠:Day 0 (PRE), Day 28 or Day 56 (POST)
|
GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Number of Subjects Who Seroconverted
時間枠:Day 28 or Day 56
|
Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Seroprotected Subjects
時間枠:Day 0 (PRE), Day 28 or Day 56 (POST)
|
A seroprotected subject is a subject with a serum anti-HA titer ≥ 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Seroconversion Factor
時間枠:Day 28 or Day 56
|
Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
|
Number of Subjects Reporting Solicited Local Symptoms
時間枠:During a 4-day follow-up period after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Solicited General Symptoms
時間枠:During a 4-day follow-up period after vaccination
|
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
時間枠:During a 28-day follow-up period after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
|
During a 28-day follow-up period after vaccination
|
|
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
時間枠:During the entire study (Day 0 until Month 6)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6)
|
|
Number of Subjects Reporting Rare Serious Events
時間枠:During the entire study (Day 0 until Month 6)
|
Rare serious events have an occurrence rate of 1/300 (0.3%).
|
During the entire study (Day 0 until Month 6)
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Li-Kim-Moy J, Wood N, Jones C, Macartney K, Booy R. Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children. Pediatr Infect Dis J. 2018 Oct;37(10):971-975. doi: 10.1097/INF.0000000000001949.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 111751
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
試験データ・資料
-
データセット仕様
情報識別子:111751情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
インフォームド コンセント フォーム
情報識別子:111751情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
統計分析計画
情報識別子:111751情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
注釈付き症例報告書
情報識別子:111751情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
臨床研究報告書
情報識別子:111751情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
個人参加者データセット
情報識別子:111751情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
-
研究プロトコル
情報識別子:111751情報コメント:For additional information about this study please refer to the GSK Clinical Study Register
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。